Simple Summary Breast cancer is the most common cancer among women. It is estimated
that 2.3 million new cases of BC are diagnosed globally each year. Based on mRNA gene …

Breast cancer is a serious health problem worldwide, representing the second cause of
death through malignancies among women in developed countries. Population …

Background AKT pathway activation is implicated in endocrine-therapy resistance. Data on
the efficacy and safety of the AKT inhibitor capivasertib, as an addition to fulvestrant therapy …

Background The recurrence score based on the 21-gene breast-cancer assay has been
clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human …

Introduction Extensive research is directed to uncover new biomarkers capable to stratify
breast cancer patients into clinically relevant cohorts. However, the overall performance …

Background Ribociclib has been shown to have a significant overall survival benefit in
patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 …

Summary Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant
showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced …

PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
recurrence or have distant recurrence with currently available standard therapies. However …

There are well-established disparities in cancer incidence and outcomes by race/ethnicity
that result from the interplay between structural, socioeconomic, socio-environmental …

Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …